Clinical Research Directory
Browse clinical research sites, groups, and studies.
Myo-Inositol and Folic Acid for Improving Inflammation in Polycystic Ovary Syndrome
Sponsor: Khyber Medical University Peshawar
Summary
Polycystic Ovary Syndrome (PCOS) is a common endocrine and metabolic disorder affecting women of reproductive age and may be associated with chronic low-grade systemic inflammation. This clinical trial aims to evaluate the combined effect of Myo-Inositol and Folic Acid on systemic inflammatory markers, specifically the Neutrophil-to-Lymphocyte Ratio (NLR) and C-reactive protein (CRP), in women with PCOS. The study will compare the effects of Myo-Inositol plus Folic Acid with Metformin plus Folic Acid over a 3-month treatment period. Eligible participants will be randomly assigned to one of the two treatment groups and will take their assigned treatment daily for 3 months. Participants will attend monthly follow-up visits to assess treatment adherence, clinical progress, and any adverse effects. Blood samples will be collected at baseline and after completion of the 3-month intervention to measure NLR and CRP. Participants will also be instructed to record relevant symptoms and report any side effects experienced during the study. The primary purpose of the study is to determine whether Myo-Inositol and Folic Acid reduce NLR and CRP compared with Metformin and Folic Acid in women with PCOS.
Official title: Combined Effect of Myo-Inositol and Folic Acid on Neutrophil to Lymphocyte Ratio and C - Reactive Protein in Patients With Polycystic Ovarian Syndrome
Key Details
Gender
FEMALE
Age Range
25 Years - 35 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-10-11
Completion Date
2026-09-30
Last Updated
2026-09-15
Healthy Volunteers
No
Interventions
myo-inositol 2000 gm + folic acid 200 mcg
This study involves two active treatment interventions aimed at evaluating their comparative effects on inflammatory markers in patients with Polycystic Ovarian Syndrome (PCOS). In the intervention arm, participants will receive a combination of Myo-Inositol and Folic Acid administered orally on a daily basis for a duration of three months. Myo-Inositol is selected for its role as an insulin-sensitizing agent that improves intracellular signaling and metabolic function, while Folic Acid is included for its antioxidant properties and potential to reduce homocysteine levels and systemic inflammation. In the control arm, participants will receive Metformin in combination with Folic Acid, also administered orally on a daily basis for three months. Metformin is a well-established insulin-sensitizing drug widely used in the management of PCOS and serves as the standard comparator in this study. Both interventions are intended to improve metabolic and inflammatory status; however, they diff
Locations (1)
Peshawar Health Center
Peshawar, Kpk, Pakistan